Katherine Tweden - EnteroMedics Insider

EnteroMedics Inc -- USA Stock  

USD 1.98  0.07  3.41%

Co-Founder and VP of Clinical and Regulatory

Dr. Katherine S. Tweden, Ph.D., was promoted as Senior Vice President Research of the Company. She was the Vice President Clinical and Regulatory of EnteroMedics Inc., since May 2011. Prior to that Dr. Tweden served as our Vice President of Research and Clinical from September 2008 to May 2011 and our Vice President of Research from January 2003 to September 2008. From November 2002 to January 2003, Dr. Tweden was a consultant to Venturi Group, a medical device incubator company. From January 2003 through August 2004, Dr. Tweden worked for Venturi Development Inc. as a consultant to us. From July 1997 to October 2002, Dr. Tweden held positions including Director of Research and Vice President of Research for HeartStent Corporationrationration. From September 1990 to June 1997, Dr. Tweden held the positions of Senior Research Scientist and Principal Research Scientist at St. Jude Medical, Inc
Age: 53  Founder Since 2015      
651-634-3003  http://www.enteromedics.com
Tweden received a Bachelor of Arts in chemistry from Gustavus Adolphus College and a Master?s degree and Ph.D. in biomedical engineering from Iowa State University.

Management Efficiency

The company has return on total asset (ROA) of (48.42) % which means that it has lost $48.42 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (146.32) % meaning that it created substantial loss on money invested by shareholders.

Entity Summary

EnteroMedics Inc., a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. EnteroMedics Inc (ETRM) is traded on Nasdaq Capital Markets in USA. It is located in MINNESOTA, U.S.A and employs 37 people. EnteroMedics is listed under Medical Equipment category by Fama And French industry classification.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add EnteroMedics Inc to your portfolio

Top Management

EnteroMedics Inc Leadership Team
Jon Tremmel, CEO
Peter Delange, President
Bradford Hancock, Executive
Scott Youngstrom, CFO
Dan Gladney, CEO
Nicholas Teti, Director
Carl Goldfischer, Director
Catherine Friedman, Director
Michael Mashaal, Director, Ph.D
Lori McDougal, Director
Gary Blackford, Director
Nick Ansari, President
Scott Shikora, President
Anthony Jansz, Director
Adrianus Donders, SVP
Katherine Tweden, Founder
Mark Knudson, Chairman, Ph.D
Gregory Lea, CFO
Paul Hickey, President
Bobby Griffin, Director
Tonya Dowd, President
Naqeeb Ansari, President

Stock Performance

EnteroMedics Performance Indicators